

## Disclosures

### Personal Commercial (15)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
American Regent, Inc	Research/Research Grants	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Biofourmis	Research/Research Grants ‡ AIM-POWER	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Bodyport	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Bodyport	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Cardionomic	Data Safety Monitoring Board	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Cytokinetics	Research/Research Grants	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Johnson & Johnson	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
LivaNova	Consultant Fees/Honoraria	Modest (< \$5,000)	
Myovant	Other - <i>Clinical endpoint committee member</i>	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Natera	Other - <i>Steering Committee</i>	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
NHLBI	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Novartis Corporation	Research/Research Grants ‡ CONNECT-HF	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
NovoNordisk	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Story Health	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Zoll	Other - <i>Speaking and Consulting</i>	Modest (< \$5,000)	

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (2)

Trial Name	Trial Sponsor	Trial Funding Source
DEFINE-HT	Natera	
PARAGLIDE	Novartis Corporation	

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 9/27/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

## **Confidentiality, Disclosure and Assignment Agreement** | Signed on 9/27/2024

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

## **Embargo** | Signed on 9/27/2024

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

## **On-Going Obligation Agreement** | Signed on 9/27/2024

---

### **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.